294.52
  Price0.81%   +2.36
(After Hours: 293.70 -0.82 -0.28%)
Aug-12-22 10:23AM Is This Unknown Growth Stock a Buy After Its Blast Off?The Motley Fool
06:05AM The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex PharmaceuticalsZacks Investment Research
Aug-11-22 11:25AM Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More UpdatesZacks Investment Research
05:52AM Big Pharma Upheaval Coming -- This Stock Is Poised to Skyrocket, AnywayThe Motley Fool
Aug-09-22 09:05AM CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss EstimatesZacks Investment Research
Aug-06-22 10:23AM 2 Top Biotech Stocks Defying the Bear MarketThe Motley Fool
01:07AM Vertex Q2: Betting Big On Quality Over QuantitySeeking Alpha
Aug-05-22 05:19AM Why Vertex Pharmaceuticals Stock Was Soaring TodayThe Motley Fool
02:15AM Where Vertex Pharmaceuticals Stands With AnalystsBenzinga
Aug-05-22 09:33AM Vertex (VRTX) Beats on Q2 Earnings, Ups 2022 Sales GuidanceZacks Investment Research
05:30AM Vertex Pharmaceuticals (VRTX) Q2 2022 Earnings Call TranscriptThe Motley Fool
Aug-04-22 05:35AM Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue EstimatesZacks Investment Research
Aug-03-22 09:48AM Drug, Biotech Stocks' Q2 Earnings on Aug 4: LLY, AMGN & MoreZacks Investment Research
Jun-04-22 05:57AM My 3 Highest-Conviction Growth Stocks Right NowThe Motley Fool
Jun-03-22 10:00AM 2 Green Flags for Vertex Pharmaceuticals' FutureThe Motley Fool
Jun-01-22 10:08AM Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022Benzinga
May-28-22 06:14AM 3 Simple Steps to Make a Fortune When Market Corrections ComeThe Motley Fool
May-26-22 06:00AM 3 Healthcare Stocks You Can Buy and Hold for the Next DecadeThe Motley Fool
May-24-22 06:20AM Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?Zacks Investment Research
May-23-22 11:39AM What 5 Analyst Ratings Have To Say About Vertex PharmaceuticalsBenzinga
10:33AM Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022Benzinga
May-23-22 09:34AM Penny Stocks To Buy Now? 4 To Watch Under $1PennyStocks
06:00AM Market Dip: Here's How to Invest SafelyThe Motley Fool
May-22-22 08:10AM Biotech is in ‘a Category 5 storm, the same as energy in 2020’ — why contrarians say the sector is a buyMarketWatch
06:00AM Have $2,000? 2 Market Crash-Ready Stocks to BuyThe Motley Fool
May-21-22 07:05AM 3 Stocks That Could Make You a Fortune Over the Next 10 YearsThe Motley Fool
May-20-22 10:34AM ‘The capitulation model for biotech is a Category 5 storm, the same as energy in 2020’ — why contrarians say the sector is a buyMarketWatch
May-19-22 07:09AM The Zacks Analyst Blog Highlights Alibaba, McDonald, Advanced Micro Devices, Abbott Laboratories, and Vertex PharmaceuticalsZacks Investment Research
05:21AM 3 of the Smartest Stocks to Buy in a Fed-Induced Bear MarketThe Motley Fool
May-18-22 02:53AM Top Stock Reports for Alibaba, McDonald's & Advanced Micro DevicesZacks Investment Research
09:06AM Vertex (VRTX) Outperforms Industry This Year So Far: Here's WhyZacks Investment Research
May-16-22 02:23AM CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed DrugsZacks Investment Research
06:20AM Should You Invest in the VanEck Biotech ETF (BBH)?Zacks Investment Research
May-14-22 06:30AM Here's the No. 1 Reason to Buy Vertex Pharmaceuticals NowThe Motley Fool
May-13-22 11:45AM 2 Stocks With 75% to 183% Upside, According to Wall StreetThe Motley Fool
10:32AM These 5-Stock Samplers Have Gotten Whacked. And That's OKThe Motley Fool
May-13-22 08:42AM The Zacks Analyst Blog Highlights Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven PharmaceuticalZacks Investment Research
May-12-22 09:11AM Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory NewsZacks Investment Research
05:21AM Got $3,000? These 3 Stocks Are Screaming Buys During the Market Sell-OffThe Motley Fool
May-10-22 02:36AM Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top EstimatesZacks Investment Research
02:23AM Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial DataBenzinga
May-10-22 10:30AM CRISPR Therapeutics (CRSP) Q1 Earnings & Sales Miss EstimatesZacks Investment Research
May-09-22 02:42AM Intercept (ICPT) Q1 Earnings Top, Ocaliva Sales Miss EstimatesZacks Investment Research
11:09AM Viatris' (VTRS) Q1 Earnings Beat, Revenues Miss EstimatesZacks Investment Research
May-09-22 11:05AM Alcon (ALC) to Report Q1 Earnings: What's in the Cards?Zacks Investment Research
06:00AM Is Vertex Pharmaceuticals' Billion-Dollar Business Getting Even Bigger?The Motley Fool
May-09-22 05:54AM 3 Safe Stocks to Buy That Are Crushing the MarketThe Motley Fool
May-06-22 01:23AM Endo (ENDP) Beats on Q1 Earnings, Guides Weak Q2 ResultsZacks Investment Research
12:43PM Radius (RDUS) Q1 Loss Wider Than Expected, Revenues DeclineZacks Investment Research
May-06-22 11:37AM Ultragenyx's (RARE) Q1 Earnings & Revenues Miss EstimatesZacks Investment Research
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Cap:    |  Volume (24h):